Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Steve Harmon who wrote (1298)	7/28/1998 9:04:00 AM
From: Howard Frederick	Read Replies (1) \| Respond to of 2742

//Pasteur Merieux also has a interest in IL-1's cancer indications also. This of course will increase the value of IL-1 even more. // Do you know for sure that the cancer indications weren't included in the initial agreement? Rick Harmon had posted the agreement hadn't been finalized.

To: Steve Harmon who wrote (1298)	7/28/1998 10:51:00 AM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 2742

The lead article in this week's BioCentury is a very informative review of vaccine development activities and partnering opportunities. Definitely worth tracking down a copy since CIST's partner, Pasteur Merieux Connaught, is one of the companies featured. Here are the intro paragraphs: <<Partnering opportunities - Pharmaccines Vaccines for a long time have been considered a low margin business, but with the advent of recombinant technologies and a better understanding of the biology of the immune system, the sector looks poised for dramatic growth. This is good news for biotech, as the leading pharmaceutical players such as Pasteur Merieux Connaught and SmithKline Beecham appear to be doing much of their discovery and development work in partnership with biotech companies. This is particularly true with the so-called therapeutic vaccines or pharmaccines. These, unlike conventional vaccines, do not prevent disease from occurring but instead use the immune system to help prolong life. "We are still mostly focused on prophylactics but it is only logical that as we further understand the mechanisms of the human immune system we should want to develop products that help the immune system fight off diseases such as cancer once they have started," said Pierre Meulien, vice president of R&D at Pasteur Merieux Connaught, the world's leading vaccines company.>> Rudy